TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04387175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere Motion 3D Class III Appliance
Description: The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Description: The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
Study: NCT05959629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterlase Express™, BIOLASE®
Description: Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hypochlorite
Description: Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
Study: NCT04486482

Intervention type: OTHER
Group type: OTHER
Intervention: KB109 + Self Supportive Care (SSC)
Description: KB109 is a novel glycan

Intervention type: OTHER
Group type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study: NCT03181087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord MSCs
Description: Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
Study: NCT03900988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: 5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study: NCT05290090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, Zanubrutinib and RCHOP
Description: chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.
Study: NCT05908526

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline surveys, Cognitive testing and EMAs
Description: Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline surveys, Cognitive testing and EMAs
Description: Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Actiwatch
Description: Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actiwatch
Description: Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant (or placebo)
Description: FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive substance that looks like the drug or treatment being tested.
Study: NCT05028517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMF Connect
Description: The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMF Connect
Description: The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
Study: NCT06218381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Brief Exposure to Combat Images
Description: In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
Study: NCT05786482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mind-body wellness program
Description: Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mind-body wellness program + Weekly Check-ins
Description: Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
Study: NCT05491317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1042
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT05409859

Intervention type: OTHER
Intervention: Manual therapies
Description: Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
Study: NCT04657081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine (ASTX727)
Description: Route of administration: oral in the form of a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Route of administration: oral in the form of a tablet
Study: NCT05057091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation
Description: For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation
Description: For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2- Side-Lying Lumbar Spinal Manipulation
Description: The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2- Side-Lying Lumbar Spinal Manipulation
Description: The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.
Study: NCT06116552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Social Stories
Description: Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less Social Stories
Description: Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
Study: NCT06120556

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
Study: NCT04633005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Rx
Description: Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
Study: NCT06120556

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
Study: NCT05976763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: undergo bone marrow biopsy
Study: NCT05032157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (blinded)
Description: LOU064 (blinded) active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (open-label)
Description: LOU064 (open-label) active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064 (open-label)
Description: LOU064 (open-label) active treatment
Study: NCT06307873

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pre and post operative POP-Q results
Description: Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pre and post operative POP-Q results
Description: Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pre and post operative PİSQ-12 results
Description: Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pre and post operative PİSQ-12 results
Description: Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
Study: NCT05519501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntrFuge System
Description: Microsized Adipose Tissue

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Offloading
Study: NCT05283720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study: NCT04943445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
Description: Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.
Description: Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
Study: NCT05283720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV); Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV); Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV; Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV; Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride [HCl]
Description: IV; Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride [HCl]
Description: IV; Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV; Injection
Study: NCT05976763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: undergo bone marrow biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05314855

Intervention type: DEVICE
Intervention: functional MRI
Description: Subjects will undergo functional MRI at 4 time points in 24 hours.

Intervention type: DEVICE
Intervention: functional MRI
Description: Subjects will undergo functional MRI at 4 time points in 24 hours.

Intervention type: DEVICE
Intervention: functional MRI
Description: Subjects will undergo functional MRI at 4 time points in 24 hours.
Study: NCT06518135

Intervention type: OTHER
Intervention: SLNB group
Description: After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
Study: NCT06066645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intraocular Implant
Description: anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent infinite
Description: Successful iStent infinite surgery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iStent infinite
Description: Successful iStent infinite surgery
Study: NCT05283720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV; Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral; Tablet
Study: NCT05175547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Description: Blood pressure management with Clevidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Description: Blood pressure management with Clevidipine
Study: NCT06217458

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography
Description: The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.